File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Investigation of the efficacy of a bevacizumab-cetuximabcisplatin regimen in treating head and neck squamous cell carcinoma in mice

TitleInvestigation of the efficacy of a bevacizumab-cetuximabcisplatin regimen in treating head and neck squamous cell carcinoma in mice
Authors
Issue Date2010
PublisherSpringer-Verlag France. The Journal's web site is located at http://www.springer.com/sgw/cda/frontpage/0,11855,4-40109-70-72816661-0,00.html?changeHeader=true
Citation
Targeted Oncology, 2010, v. 5 n. 4, p. 237-243 How to Cite?
AbstractThe efficacy of bevacizumab plus cetuximabbased chemotherapy remains unclear in head and neck squamous cell carcinoma (HNSCC). The aim of this study was to investigate the anticancer efficacy of a bevacizumabcetuximab-cisplatin triple-agent combination in treating mouse HNSCC. SCC-VII tumor-bearing C3H mice were treated with bevacizumab, cetuximab and cisplatin either alone or in various combinations. In vivo results showed that the largest delay in tumor growth and the maximum increase in survival were not in the triple-agent combination therapy, but in the bevacizumab plus cisplatin therapy. TUNEL assay showed that the apoptosis indices in bevacizumab plus cisplatin group and a triple-agent combination group were 31.6±12.0% and 6.9±1.3%, respectively. Western blot showed that down-regulation of Bcl-2 and up-regulation of cleaved caspase-3 contributed to the anticancer effect of a triple-agent combination and bevacizumab plus cisplatin. Moreover, the maximum level of cleaved caspase-3 expression was not found in the tripleagent combination group but in the bevacizumab plus cisplatin group. Bevacizumab plus cisplatin therapy is better than bevacizumab-cetuximab-cisplatin triple therapy in the mouse HNSCC model. Our findings suggest that the bevacizumab-cetuximab- cisplatin regimen may not be suitable for treating HNSCC. © Springer-Verlag 2010.
Persistent Identifierhttp://hdl.handle.net/10722/154662
ISSN
2015 Impact Factor: 3.197
2015 SCImago Journal Rankings: 1.340
ISI Accession Number ID
Funding AgencyGrant Number
National Natural Science Foundation of China39470754
National "985 Project" of China985-2-040-115
Funding Information:

We thank Dr. Nianhui Cui for providing the SCC-VII cell line for the study. This study was supported by the National Natural Science Foundation of China (39470754) and the National "985 Project" of China (985-2-040-115).

References

 

DC FieldValueLanguage
dc.contributor.authorWang, Yen_US
dc.contributor.authorDong, Len_US
dc.contributor.authorBi, Qen_US
dc.contributor.authorLi, Xen_US
dc.contributor.authorWu, Den_US
dc.contributor.authorGe, Xen_US
dc.contributor.authorZhang, Xen_US
dc.contributor.authorFu, Jen_US
dc.contributor.authorZhang, Cen_US
dc.contributor.authorWang, Cen_US
dc.contributor.authorLi, Sen_US
dc.date.accessioned2012-08-08T08:26:48Z-
dc.date.available2012-08-08T08:26:48Z-
dc.date.issued2010en_US
dc.identifier.citationTargeted Oncology, 2010, v. 5 n. 4, p. 237-243en_US
dc.identifier.issn1776-2596en_US
dc.identifier.urihttp://hdl.handle.net/10722/154662-
dc.description.abstractThe efficacy of bevacizumab plus cetuximabbased chemotherapy remains unclear in head and neck squamous cell carcinoma (HNSCC). The aim of this study was to investigate the anticancer efficacy of a bevacizumabcetuximab-cisplatin triple-agent combination in treating mouse HNSCC. SCC-VII tumor-bearing C3H mice were treated with bevacizumab, cetuximab and cisplatin either alone or in various combinations. In vivo results showed that the largest delay in tumor growth and the maximum increase in survival were not in the triple-agent combination therapy, but in the bevacizumab plus cisplatin therapy. TUNEL assay showed that the apoptosis indices in bevacizumab plus cisplatin group and a triple-agent combination group were 31.6±12.0% and 6.9±1.3%, respectively. Western blot showed that down-regulation of Bcl-2 and up-regulation of cleaved caspase-3 contributed to the anticancer effect of a triple-agent combination and bevacizumab plus cisplatin. Moreover, the maximum level of cleaved caspase-3 expression was not found in the tripleagent combination group but in the bevacizumab plus cisplatin group. Bevacizumab plus cisplatin therapy is better than bevacizumab-cetuximab-cisplatin triple therapy in the mouse HNSCC model. Our findings suggest that the bevacizumab-cetuximab- cisplatin regimen may not be suitable for treating HNSCC. © Springer-Verlag 2010.en_US
dc.languageengen_US
dc.publisherSpringer-Verlag France. The Journal's web site is located at http://www.springer.com/sgw/cda/frontpage/0,11855,4-40109-70-72816661-0,00.html?changeHeader=trueen_US
dc.relation.ispartofTargeted Oncologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Monoclonal - Administration & Dosage - Pharmacologyen_US
dc.subject.meshAntibodies, Monoclonal, Humanizeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Pharmacologyen_US
dc.subject.meshApoptosis - Drug Effectsen_US
dc.subject.meshCarcinoma, Squamous Cell - Drug Therapy - Pathologyen_US
dc.subject.meshCaspase 3 - Biosynthesisen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshCisplatin - Administration & Dosage - Pharmacologyen_US
dc.subject.meshDown-Regulation - Drug Effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHead And Neck Neoplasms - Drug Therapy - Pathologyen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred C3hen_US
dc.subject.meshProto-Oncogene Proteins C-Bcl-2 - Biosynthesisen_US
dc.subject.meshUp-Regulation - Drug Effectsen_US
dc.titleInvestigation of the efficacy of a bevacizumab-cetuximabcisplatin regimen in treating head and neck squamous cell carcinoma in miceen_US
dc.typeArticleen_US
dc.identifier.emailZhang, C:zhangcf@hku.hken_US
dc.identifier.authorityZhang, C=rp01408en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s11523-010-0164-3en_US
dc.identifier.pmid21086056en_US
dc.identifier.scopuseid_2-s2.0-79952708655en_US
dc.identifier.hkuros183654-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79952708655&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume5en_US
dc.identifier.issue4en_US
dc.identifier.spage237en_US
dc.identifier.epage243en_US
dc.identifier.isiWOS:000285208800003-
dc.publisher.placeFranceen_US
dc.identifier.scopusauthoridWang, Y=35847885800en_US
dc.identifier.scopusauthoridDong, L=36445358100en_US
dc.identifier.scopusauthoridBi, Q=36445153200en_US
dc.identifier.scopusauthoridLi, X=36445926200en_US
dc.identifier.scopusauthoridWu, D=7404298374en_US
dc.identifier.scopusauthoridGe, X=12762412200en_US
dc.identifier.scopusauthoridZhang, X=36447215800en_US
dc.identifier.scopusauthoridFu, J=53879609400en_US
dc.identifier.scopusauthoridZhang, C=7405494609en_US
dc.identifier.scopusauthoridWang, C=35187959300en_US
dc.identifier.scopusauthoridLi, S=35187313600en_US
dc.identifier.citeulike8300701-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats